This training course about virus filtration will provide the attendees with a profound understanding about the current state of the art around this topic. A thorough introduction to virus filtration will be given as well as in-depth background and a mechanistic understanding about the principles of (parvo-) virus retention will be available to the attendees at the end of the course. An interactive session will address the question of “how to design an efficient virus filtration process?” and a practical session will provide some hands-on experiencewith lab- and production-scale virus filter modules.
Who Should Attend
- R&D scientists
- Supervisors in manufacturing
- QA Manager (Regulatory Affairs, Pathogen Safety)
Upon completion of the course the participant
- have understood virus filtration principles
- ability to set-up and handle virus filtration processes
- have an overview of filter types and material
- have understood challenges of different matrices
- have gained hands-on experience with virus filters / process
- have understood principles/requirements of filter integrity
- have an overview of current guidelines and regulations
Sebastian B. Teitz, PhD, Lab- & Product Manager, Asahi Kasei Bioprocess Europe
Sebastian Teitz graduated from University of Cologne with a diploma in Genomic Imprinting, followed with a PhD in the Analysis of O-glycosylated Proteins. Sebastian has previously worked at Fred Hutchinson Cancer Research Center (Seattle, WA), looking into Cytomegalovirus and its role in Graft vs. Host Disease and Transplant Rejection and at NewLab BioQuality / Charles River as the Project Manager of Virus Clearance Studies, focusing on scientific liaison with customers. At Asahi his focus lies with the technical, scientific and regulatory support of customers and internal entities, as well as representation in various industry organizations, such as the PDA, BPOG
Andy Bailey, CEO, ViruSure GmbH
Andy Bailey is a virologist who served for 9 years at the MRC Virology Unit in Glasgow. In 1995, he moved to the industry sector, initially as Director of Virus Validation services with Q-One Biotech Ltd, and later at the Pathogen Safety group of Baxter Healthcare in Vienna, Austria. Over the last 20 years Andy has been actively involved in the virus and prion safety field, presenting at numerous regulatory agencies either in support of products at the UK MHRA, German PEI, French AFFSAPS, US FDA, KFDA (Korea), EMEA and JMHLW (Japan) supporting regulatory submissions for various products. He has extensive experience in regulatory affairs and virus safety issues. Since 2005 he has been the founder and CEO of ViruSure in Vienna, Austria, a company specialising in the virus and prion safety of biopharmaceutical products
Franz Nothelfer, Consultant
Franz Nothelfer is consultant for downstream processing and viral safety. Before his retirement in 2017, he was heading a position as associate director Protein Science at Boehringer Ingelheim Pharma (BI), responsible for the development of novel purification processes for therapeutic proteins and monoclonal antibodies. A major task of his team was the transfer, establishment and optimization of purification processes of customers to achieve robust and economic manufacturing processes. Franz started his career in 1971 at Dr. Karl Thomae GmbH (later BI). In 1979 he joined the newly founded iotechnology department and was involved in the first process transfer of a recombinant protein to BI in 1985. During his career at Boehringer Ingelheim he took over several challenging positions.
Michael Lasse, PhD, Study Director Supervisor, Charles River Biologics Testing Solutions
Michael Lasse graduated from the University of Rostock with a diploma in Biology working on programmed cell death in neural progenitor cells. At the University of Cologne his PhD studies in Biochemistry focused on recombinant protein expression of apoptosis relevant membrane proteins, chromatographic purification techniques and post-translational lipid modifications. Michael Lasse joined Charles River as a study director for viral clearance studies and is currently supervising an operational team within the viral clearance department focusing on chromatography and related topics like continuous processing.